In patients with NMO, when combined with immunosuppressants, satralizumab reduced the risk of relapse compared to a placebo by blocking the IL-6 receptor, showing the involvement of IL-6 in NMO [86]. This evidence concerns the gene IL6 and neuromyelitis optica.